Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

References for PMC Articles for PubMed (Select 23509508)

1.

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.

Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.

2.

Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee.

Can J Cardiol. 2011 Jan-Feb;27(1):74-90. doi: 10.1016/j.cjca.2010.11.007.

PMID:
21329865
3.

Atrial fibrillation and stroke management: present and future.

Holmes DR.

Semin Neurol. 2010 Nov;30(5):528-36. doi: 10.1055/s-0030-1268861. Epub 2011 Jan 4. Review.

PMID:
21207345
4.

Newly identified events in the RE-LY trial.

Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators.

N Engl J Med. 2010 Nov 4;363(19):1875-6. doi: 10.1056/NEJMc1007378. No abstract available.

5.

The evolving field of stroke prevention in patients with atrial fibrillation.

Ezekowitz MD, Aikens TH, Brown A, Ellis Z.

Stroke. 2010 Oct;41(10 Suppl):S17-20. doi: 10.1161/STROKEAHA.110.598201. Review.

6.

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators.

Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4.

PMID:
20801496
7.

Stroke prevention and treatment.

Marsh JD, Keyrouz SG.

J Am Coll Cardiol. 2010 Aug 24;56(9):683-91. doi: 10.1016/j.jacc.2009.12.072. Review.

8.

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J.

Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29. Review.

9.

Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Siddiqui FM, Qureshi AI.

Expert Opin Pharmacother. 2010 Jun;11(8):1403-11. doi: 10.1517/14656566.2010.482931. Review.

PMID:
20446854
10.

Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care.

Bungard TJ, Gardner L, Archer SL, Hamilton P, Ritchie B, Tymchak W, Tsuyuki RT.

Open Med. 2009 Feb 2;3(1):e16-21.

11.

Dabigatran versus warfarin in patients with atrial fibrillation.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators.

N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.

12.

Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature.

Dolan G, Smith LA, Collins S, Plumb JM.

Curr Med Res Opin. 2008 May;24(5):1459-72. doi: 10.1185/030079908X297349 . Epub 2008 Apr 9. Review.

PMID:
18402715
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk